ethylhydrazine oxalate | 35532-19-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: ethylhydrazine oxalate
• 英文别名: Oxalic acid, bis(2-ethylhydrazide)；1-N',2-N'-diethylethanedihydrazide
• CAS: 35532-19-5
• 化学式: C₆H₁₄N₄O₂
• 分子量: 174.203
• InChiKey: VMVNTBWTFQFSGG-UHFFFAOYSA-N

物化性质

• 熔点：
  202.5-204.0 °C
• 密度：
  1.108±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  82.3
• 氢给体数：
  4
• 氢受体数：
  4

安全信息

• 海关编码：
  2928000090

反应信息

• 作为反应物：
  描述：

  ethylhydrazine oxalate 在 硫酸 、 sodium nitrite 作用下， 生成 oxalic acid bis-(N'-ethyl-N'-nitroso-hydrazide)
  参考文献：
  名称：

  Fischer,E.; Troschke, Justus Liebigs Annalen der Chemie, 1879, vol. 199, p. 297

  摘要：

  DOI：
• 作为产物：
  描述：

  Bis-(acetaldehyd)oxalylhydrazon 在 platinum(IV) oxide 氢气 作用下， 以 乙醇 为溶剂， 生成 ethylhydrazine oxalate
  参考文献：
  名称：

  A Study of the Inhibitory Effect of Various Hydrazides on Monoamine Oxidase in vitro and in vivo

  摘要：

  DOI：

  10.1021/jm50018a004

文献信息

• Discovery of Pyrazolocarboxamides as Potent and Selective Receptor Interacting Protein 2 (RIP2) Kinase Inhibitors
  作者：Curt D. Haffner、Adam K. Charnley、Christopher J. Aquino、Linda Casillas、Máire A. Convery、Julie A. Cox、Mark A. Elban、Nicole C. Goodwin、Peter J. Gough、Pamela A. Haile、Terry V. Hughes、Beth Knapp-Reed、Constantine Kreatsoulas、Ami S. Lakdawala、Huijie Li、Yiqian Lian、David Lipshutz、John F. Mehlmann、Michael Ouellette、Joseph Romano、Lisa Shewchuk、Arthur Shu、Bartholomew J. Votta、Huiqiang Zhou、John Bertin、Robert W. Marquis

  DOI：10.1021/acsmedchemlett.9b00141

  日期：2019.11.14

  Herein we report the discovery of pyrazolocarboxamides as novel, potent, and kinase selective inhibitors of receptor interacting protein 2 kinase (RIP2). Fragment based screening and design principles led to the identification of the inhibitor series, and X-ray crystallography was used to inform key structural changes. Through key substitutions about the N1 and C5 N positions on the pyrazole ring significant

  在这里，我们报告吡唑并羧酰胺作为受体相互作用蛋白2激酶（RIP2）的新型，有效和激酶选择性抑制剂的发现。基于片段的筛选和设计原理导致了抑制剂系列的鉴定，并使用X射线晶体学分析了关键的结构变化。通过在吡唑环上的N1和C5 N位置进行关键取代，可以实现显着的激酶选择性和效力。桥连的双环吡唑并羧酰胺11代表RIP2的选择性和有效抑制剂，将允许更详细地研究RIP2抑制作为自身炎症性疾病的治疗靶标。
• [EN] PHARMACEUTICAL COMPOUNDS<br/>[FR] COMPOSÉS PHARMACEUTIQUES
  申请人：REVIRAL LTD

  公开号：WO2021084280A1

  公开（公告）日：2021-05-06

  Benzodiazepine derivatives of formula (I): (I) wherein: each of R1 and R2 is independently H or halo; R3 is H, C1-C6 alkyl or -NHR8; either (i), a, c and c are all bonds, with, b,d and f absent; or b, d, and f are all bonds, with a, c, and c absent; R4 is H or a group selected from C1-C6 alkyl, C3-C6 cycloalkyl and 4- to 10-membered heterocyclyl, the group being unsubstituted or substituted; R5 is H or halo; R6 is -OR8, -NR8R9 or -R8; R7 is H or halo; each of R8 and R9 is independently H or a group selected from C1-C6 alkyl, C3-C6 cycloalkyl and 4- to 10-membered heterocyclyl, the group being unsubstituted or substituted; n is 1 or 2; and one of V, W and X is N or CH and the other two are CH; and the pharmaceutically acceptable salts thereof are inhibitors of RSV and can therefore be used to treat or prevent an RSV infection.

  苯二氮卓类化合物的结构式(I)：(I)其中：R1和R2中的每一个独立地是H或卤素；R3是H、C1-C6烷基或-NHR8；要么(i)、a、c和c都是键，b、d和f不存在；要么b、d和f都是键，a、c和c不存在；R4是H或选择自C1-C6烷基、C3-C6环烷基和4-到10-成员杂环基的基团，该基团未取代或取代；R5是H或卤素；R6是-OR8、-NR8R9或-R8；R7是H或卤素；R8和R9中的每一个独立地是H或选择自C1-C6烷基、C3-C6环烷基和4-到10-成员杂环基的基团，该基团未取代或取代；n为1或2；V、W和X中的一个是N或CH，另外两个是CH；以及其药学上可接受的盐是RSV的抑制剂，因此可用于治疗或预防RSV感染。
• 6-AMINOPYRIDIN-3-YL PYRAZOLES AS MODULATORS OF RORgT
  申请人：Janssen Pharmaceutica NV

  公开号：US20190382373A1

  公开（公告）日：2019-12-19

  The present invention comprises compounds of Formula I. wherein: R 1 , Q, R 3 , R 4 , R 5 , R 6 , A 1 , and A 2 are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-γ-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.

  本发明涵盖了Formula I中的化合物，其中：R1、Q、R3、R4、R5、R6、A1和A2在规范中有定义。该发明还涵盖了一种治疗或改善ROR-γ-t介导的综合征、疾病或疾病的方法，包括综合征、疾病或疾病选自风湿性关节炎、银屑病性关节炎和银屑病的群体。该发明还涵盖了通过给哺乳动物施用至少一种Formula I化合物的治疗有效量来调节RORγt活性的方法。
• ULK1 inhibitors and methods using same
  申请人：SALK INSTITUTE FOR BIOLOGICAL STUDIES

  公开号：US10266549B2

  公开（公告）日：2019-04-23

  In certain aspects, the invention provides a method for treating a disease or condition in a subject, the method comprising co-administering to a subject in need thereof a therapeutically effective amount of at least one ULK1-inhibiting pyrimidine, and a therapeutically effective amount of an mTOR inhibitor.

  在某些方面，本发明提供了一种治疗受试者疾病或病症的方法，该方法包括向有需要的受试者联合施用治疗有效量的至少一种ULK1抑制嘧啶和治疗有效量的mTOR抑制剂。
• NOVEL ULK1 INHIBITORS AND METHODS USING SAME
  申请人：SALK INSTITUTE FOR BIOLOGICAL STUDIES

  公开号：US20170342088A1

  公开（公告）日：2017-11-30

  In certain aspects, the invention provides a method for treating a disease or condition in a subject, the method comprising co-administering to a subject in need thereof a therapeutically effective amount of at least one ULK1-inhibiting pyrimidine, and a therapeutically effective amount of an mTOR inhibitor.